Interactive Decision Support Tool on BsAb AE Management
Point-of-Care, Digital, Interactive Decision Support Tool (IDST) for the Prevention/Management of AEs During Treatment with BsAbs in MM

Released: January 06, 2025

Expiration: January 05, 2026

Instructions

This Interactive Decision Support Tool provides treatment recommendations from 3 experts based on the specific patient and disease characteristics you enter in the tool. It is recommended that you have as much information as possible available before you begin.

You will be prompted to provide specific information about your patient including bispecific antibody therapy, AE occurrence, specific AE, and AE grade.

Click on your selections. Your choices can be changed at any time simply by selecting the [change] icon by the question you want to change and entering a new choice.

Additional information on each variable/characteristic and why it is important for making management decisions is available by clicking on the [i] icon after each selection.

When all patient characteristics are entered, you will be asked to select the management option you are currently planning. Once that information is entered, you can click on Submit Patient Case to view the expert recommendations.

After reviewing your case-specific recommendations, you will be asked brief questions about how the recommendations influenced your decision-making. You will then be able to enter a new case scenario by clicking the Start New Case button.

You will also have the following options:

  • Print/download the recommendations along with a summary of the patient characteristics and selected therapy you entered by clicking the Case Summary button.
  • View an Additional Considerations section covering additional factors that may affect bispecific antibody AE management as well as key considerations before initiating bispecific antibody therapy.

Access to and use of this Interactive Decision Support Tool titled, “Prevention and Management of AEs During Treatment with Bispecific Antibody Therapy in Multiple Myeloma” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on making optimal management choices for bispecific antibody therapy-related AEs in patients with R/R MM. The information provided is based on the latest prescribing information instructions and expert guidance of Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO; Melissa Pozotrigo, PharmD, BCOP; and Noopur Raje, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the Clinical Care Options material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Prevention and Management of AEs During Treatment with Bispecific Antibody Therapy in Multiple Myeloma” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2024 Clinical Care Options, LLC. All rights reserved.

Program Content